Amgen’s FORTITUDE-301 Cancer Trial Completion: What Investors Should Watch in Bemarituzumab’s Next Act
Amgen Inc (AMGN) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amgen’s latest update on its FORTITUDE-301 trial offers investors a clearer view of the company’s push into targeted cancer therapies. Officially titled “A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301),” the study aims to test how safe the drug is and whether it can shrink or control tumors in patients whose cancers show high levels of the FGFR2b marker. The focus on a biomarker-driven approach highlights Amgen’s strategy to compete in precision oncology, a growing area of interest for investors looking for durable pipelines rather than one-off products.
The trial tests bemarituzumab, an experimental cancer drug also known as AMG 552. It is given by intravenous infusion and is designed to target tumors that overexpress the FGFR2b protein, which is found in several types of solid tumors. The goal is to attack cancer cells more directly while limiting damage to normal tissue, a key selling point for next-generation oncology drugs.
FORTITUDE-301 is an interventional study, meaning patients receive active treatment rather than observation only. It runs in two sequential parts: a first phase that explores different dose levels of bemarituzumab, followed by a second phase that expands use of the best dose identified. The study is non-randomized and open-label, so everyone knows they are getting the drug, and there is no comparison placebo arm. The primary purpose is treatment-focused, centered on safety, tolerability, and early signs of benefit, which helps guide later, larger trials that might support potential approval.
The study was first submitted in April 2022, marking the formal launch of this basket trial across multiple solid tumor types. The overall study status is listed as completed, meaning active treatment and follow-up within the protocol are done, and data are now available for internal analysis and potential disclosure. The most recent update was submitted on February 3, 2026, signaling that Amgen has refreshed key information, which often aligns with new data cuts, internal reviews, or preparation for public presentations and regulatory planning. While primary and final completion dates are not detailed in the summary, the completed status and recent update timing are what matter most for investors tracking near-term catalysts.
For the market, a completed early-stage basket study like FORTITUDE-301 can be an important proof-of-concept step. If bemarituzumab shows a clean safety profile and meaningful activity in FGFR2b-positive tumors, it could strengthen Amgen’s oncology pipeline narrative and support a higher valuation multiple on its innovation portfolio. Positive data might also lift sentiment for other biomarker-driven players in the space, while putting competitive pressure on smaller biotech firms working on similar FGFR-targeted drugs. On the other hand, muted or mixed results could temper near-term enthusiasm and shift investor focus back to Amgen’s more mature assets. With precision oncology still a key theme for large-cap pharma, any clear signals from this study could influence sector rotation and appetite for targeted cancer names.
The FORTITUDE-301 study has been completed and recently updated, with further details available on the ClinicalTrials portal.
To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.
